BLVIS A Blue Vision A

The Board of Directors' resolution on the issuance of convertible loans

The Board of Directors' resolution on the issuance of convertible loans

  
  
 The Board of Directors' resolution on the issuance of convertible loans
  



April 1, 2025

Announcement no. 4



 



The Board of Directors of Pharma Equity Group has decided to issue convertible loans in accordance with the authorisation in the Company's Articles of Association under item 4.3.A. The convertible loans allow Pharma Equity Group to borrow up to DKK 6,757,895. The main terms and conditions for the convertible loans are:



 



  • The loans are granted as subordinated loan capital and are thus subordinated to the company's other creditors, except for any other similar subordinated loan capital.
  • The Lender's right to convert the loans into shares in the Company may be exercised for a period of 30 days commencing 23 calendar months after the conclusion of the convertible loan (the "Exercise Period").
  • The loans bear interest at 10% p.a. and remain without repayments until the end of the Exercise Period, after which the Company must repay the loan including interest within 60 days, however, the Company may extend the loan period by 12 months.
  • The company can choose to pay the loan including interest in shares (conversion of the promissory note).
 



Upon conversion of the loans into new shares, the new shares will be issued without pre-emptive rights for the company's existing shareholders and with the same rights as the company's existing shares. The new shares will therefore be admitted to trading on Nasdaq Copenhagen. The conversion will take place at a price corresponding to an amount of DKK 0.20 being converted into one new share in the Company with a nominal value of DKK 0.10. The maximum increase of the share capital as a result of the conversion of the convertible loans is nominally DKK 7,577,666.



 



The remaining terms of the convertible loans will be set out in the terms and conditions of the bonds, and the Board of Directors' decision on the issuance of the convertible loan will be incorporated into the Company's Articles of Association. The company's updated articles of association will be posted on the website.



 



Of the convertible loans issued by the Board of Directors as of the date of this company announcement, DKK 6,757,895 has been subscribed for and paid to the Company.



 



 



For further information, please contact:



 
 Christian Tange, CEO of Pharma Equity Group A/S, phone:



Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone:











About Pharma Equity Group A/S

Pharma Equity Group is a listed company on Nasdaq Copenhagen's main list. The company's main focus is on promoting the various drug candidates in its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on Health Care, Pharma Equity Group's primary goal is to add significant value to Reponex Pharmaceuticals' various drug candidates.

The Company is committed to providing comprehensive support, resources, and expertise to drive the development and success of these drug candidates. As a strategic partner, the Pharma Equity Group works closely with Reponex Pharmaceuticals and prioritizes the promotion of innovative medical solutions and cutting-edge treatments. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while remaining – in the longer term – open to new strategic investments for continued growth.

Attachment



EN
01/04/2025

Underlying

BLVIS ABlue Vision A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Forløb af generalforsamlingen i Pharma Equity Group A/S

Forløb af generalforsamlingen i Pharma Equity Group A/S      Forløb af generalforsamlingen i Pharma Equity Group A/S  05. maj 2025Selskabsmeddelelse nr. 6 Pharma Equity Group A/S har 16 april 2025 afholdt ordinær generalforsamling med følgende resultat:  Dirigenten gennemgik dagsordenen for dagens generalforsamling, som var: Bestyrelsens beretning om Selskabets virksomhed det forløbne årFremlæggelse af revideret årsrapport til godkendelseMeddelelse af decharge for bestyrelsen og direktionenVedtagelse af fordeling af overskud eller underskud efter forslag fra bestyrelsenFremlæggelse af v...

19h / 47m 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Passing of the General Meeting of Pharma Equity Group A/S

Passing of the General Meeting of Pharma Equity Group A/S      Passing of the General Meeting of Pharma Equity Group A/S  5th of May 2025Company Announcement no. 6 Pharma Equity Group A/S held its Annual General Meeting on 16th of April 2025 with the following results:   The chairman of the meeting reviewed the agenda for today's general meeting, which was: The Board of Directors’ report on the Company’s activities during the past yearPresentation of the audited annual report for approvalDischarge of the Board of Directors and Executive ManagementAdoption of the a...

19h / 47m 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Bestyrelsens beslutning om udstedelse af konvertible lån

Bestyrelsens beslutning om udstedelse af konvertible lån       Bestyrelsens beslutning om udstedelse af konvertible lån  1. april 2025Meddelelse nr. 4   Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af konvertible lån i henhold til bemyndigelsen i selskabets vedtægter under pkt. 4.3.A. De konvertible lån giver Pharma Equity Group mulighed for at låne op til DKK 6.757.895. Hovedvilkårene for de konvertible lån er:  Lånene er ydet som ansvarlig lånekapital og er således efterstillet selskabets øvrige kreditorer, bortset fra eventuel anden tilsvarende an...

April 1, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

The Board of Directors' resolution on the issuance of convertible loan...

The Board of Directors' resolution on the issuance of convertible loans      The Board of Directors' resolution on the issuance of convertible loans  April 1, 2025Announcement no. 4 The Board of Directors of Pharma Equity Group has decided to issue convertible loans in accordance with the authorisation in the Company's Articles of Association under item 4.3.A. The convertible loans allow Pharma Equity Group to borrow up to DKK 6,757,895. The main terms and conditions for the convertible loans are:  The loans are granted as subordinated loan capital and are thus subordinated to...

April 1, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S

Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S 25. marts 2025 Meddelelse nr. 3 Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S Bestyrelsen indkalder hermed til den ordinære generalforsamling i Pharma Equity Group A/S (“PEG” eller “Selskabet”) den: 16. april 2025, kl. 15:30 på adressen Wihlborgs KantinerSlotsmarken 152970 Hørsholm Dagsordenen for den ordinære generalforsamling er følgende: Bestyrelsens beretning om Selskabets virksomhed det forløbne årFremlæggelse af revideret årsrapport til godkendelseMeddelelse af decharge for bestyr...

March 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch